UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee		001-15875		54-1684963
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation)		File Number)		Identification No.)
501 Fifth Street				37620
Bristol, Tennessee				(Zip Code)
(Address of principal
executive offices)

(423) 989-8000
(Registrant’s telephone number, including area code)

Not applicable
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

     On May 26, 2010, King Pharmaceuticals, Inc. held its annual meeting of shareholders, at which shareholders voted on the following proposals, with the results indicated below. As of the record date for the meeting, March 30, 2010, 249,601,215 shares of our common stock were outstanding.

     1. Election of Directors. To elect ten directors to serve until the 2011 annual meeting of shareholders, or until their successors have been duly elected and qualified.

Name of Director
Nominee		Votes For				Votes Withheld				Abstained				Broker Non-Votes
Kevin S. Crutchfield			206,983,170				2,456,926				—				13,738,927
Earnest W. Deavenport, Jr.			189,028,556				20,411,540				—				13,738,927
Elizabeth M. Greetham			202,489,323				6,950,773				—				13,738,927
Philip A. Incarnati			204,653,943				4,786,153				—				13,738,927
Gregory D. Jordan, Ph.D.			204,462,427				4,977,669				—				13,738,927
Brian A. Markison			194,759,476				14,680,620				—				13,738,927
R. Charles Moyer, Ph.D.			203,831,899				5,608,197				—				13,738,927
D. Greg Rooker			202,359,964				7,080,132				—				13,738,927
Derace L. Schaffer, M.D.			203,123,279				6,316,817				—				13,738,927
Ted G. Wood			204,302,082				5,138,014				—				13,738,927

     2. Approval of Charter Amendment. To consider and act upon a proposed amendment to our Third Amended and Restated Charter providing for a majority voting standard in uncontested elections of directors and eliminating unnecessary provisions related to our previously classified Board of Directors.

Votes For		Votes Against				Abstained
215,951,302			6,437,701				790,020

     3. Reapproval of Incentive Plan Performance Goals. To reapprove the performance goals listed within our Incentive Plan, which originally were approved by our shareholders in 2005.

Votes For		Votes Against				Abstained
210,553,228			11,913,812				711,983

     4. Ratification of Independent Registered Public Accounting Firm. To ratify the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2010.

Votes For		Votes Against				Abstained
210,962,985			11,925,669				290,369

     5. Non-binding Shareholder Proposal. To consider and act upon a non-binding shareholder proposal requesting that our Board of Directors take steps to eliminate supermajority voting provisions applicable to shareholders.

Votes For		Votes Against				Abstained				Broker Non-Votes
169,607,390			39,690,332				142,374				13,738,927

     No other matters came before the annual meeting.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 1, 2010